Trial Profile

A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostamatinib (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Registrational; Therapeutic Use
Sponsors Kissei Pharmaceutical

Most Recent Events

15 Dec 2023 Status changed from active, no longer recruiting to completed.
12 Dec 2023 Results evaluating the long-term efficacy and safety of fostamatinib treatment and the off-therapy platelet count in Japanese patients with primary ITP , presented at the 65th American Society of Hematology Annual Meeting and Exposition
09 Apr 2023 Planned End Date changed from 1 Jan 2023 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com